TherapeuticsMD

TXMD

Capitalización de mercado USD 22 M

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025. License Revenues from Continuing Operations The Com.

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025. License Revenues from Continuing Operations T.

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted common share, an improvement of $1.7 million, compared to net loss from continuing operations of $(2.

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted.

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $545 thousand, or $0.05 per basic and diluted common share, compared to a net loss of $(1.05) million, or $(0.09) per basic and diluted.

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(636) thousand, or $(0.06) per basic and diluted common share, a decrease of $99 thousand, compared to net loss from continuing operations of $(8.

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(2.3) million, or $(0.20) per basic and diluted common share, a decrease of $5.4 million, compared to net loss from continuing operations of $(7.7) m.

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) thousand, or $(0.05) per basic and diluted common share, compared to a net loss of $(1.4) million, or $(0.13) per basic and d.

The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(1.05) million, or $(0.09) per basic and diluted common share, compared to a net loss of $(2.4) million, or $(0.24) per basic and dilu.